Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy

https://doi.org/10.1016/0002-9343(93)90350-XGet rights and content

Abstract

purpose: To determine the effect of long-term intermittent cyclic etidronate treatment on spinal bone density and vertebral fracture rates.

patients and methods: Postmenopausal osteoporotic women (n = 423) were randomized initially into a 2-year, double-blind, multicenter study; it was extended to a third year of blinded treatment followed by open-label treatment: 357 patients continued treatment in Year 3 (305 receiving blinded therapy and 52 receiving calcium supplementation) and 277 in Year 4. During Years 1 through 3, patients received doubleblind treatment with phosphate (1.0 g) or placebo twice daily for 3 days, etidronate (400 mg) or placebo daily for 14 days, and calcium (500 mg) daily for the remainder of each 91-day treatment cycle. During Year 4, open-label intermittent cyclic etidronate therapy (without preceding phosphate) was administered to all patients. Spinal bone density and vertebral fracture rates were the main outcome measures.

results: During Year 3, etidronate therapy maintained the significant increases in spinal bone mineral density of the first 2 years. Over the 3-year period, proximal femur bone density increased in etidronate-treated patients. Etidronate therapy for 3 years significantly decreased the vertebral fracture rate in patients at higher risk for fracture (low spinal bone density and three or more vertebral fractures at study entry), as compared with nonetidronate treatment (228 versus 412 fractures per 1,000 patient-years, respectively; p <0.05). After 1 year of open-label treatment, patients previously treated with etidronate maintained bone mass, and vertebral fracture rates in all groups were lower than in any other study period. There were no apparent serious adverse effects.

conclusions: Three years of intermittent cyclic etidronate therapy produced significant increases in spinal and hip bone density, with a significant reduction in vertebral fracture rates in patients at higher fracture risk. Maintenance of bone mass and low fracture rate were observed when etidronate was continued for an additional year.

References (26)

  • RP Heaney et al.

    Etidronate disodium in postmenopausal osteoporosis

    Clin Pharmacol Ther

    (1976)
  • C Anderson et al.

    Preliminary observations of a form of coherence therapy for osteoporosis

    Calcif Tissue Int

    (1984)
  • HK Genant et al.

    The effect of etidronate therapy in postmenopausal osteoporotic women: preliminary results

  • Cited by (388)

    • History of alendronate

      2020, Bone
      Citation Excerpt :

      However, the trials were not planned to have statistical power to detect a reduction in vertebral fracture risk. While the trials were underway, results from a trial of cyclically administered etidronate found a non-significant increase in the risk of vertebral fracture during the third year of the trial [5]. This prompted the FDA to change its guidance to require a three year duration of treatment with demonstration of a significant reduction in rates of radiographically detected vertebral fractures.

    • Metabolic Bone Disease

      2012, Kelley's Textbook of Rheumatology: Volume 1-2, Ninth Edition
    • Guidelines for the Diagnosis and Treatment of Primary Osteoporosis (2022)

      2023, Chinese Journal of Endocrinology and Metabolism
    View all citing articles on Scopus

    This work was supported by a grant from Procter & Gamble Pharmaceuticals (formerly Norwich Eaton Pharmaceuticals, Inc.).

    View full text